Charuka Wickramasinghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Charuka Wickramasinghe has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jing Li
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
11 shared publications - Andrew Wu
Johns Hopkins University 1 Whiting School of Engineering Baltimore, Maryland
8 shared publications - Yuanyuan Jiang
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
8 shared publications - Xun Bao
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
7 shared publications - Seongho Kim
Department of Oncology, Wayne State University School of Medicine, Detroit, MI
3 shared publications - Jun Jiang
Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, HWCRC, Room 523, Detroit, MI 48201, USA
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Figure S1 Population mean plasma concentration – time profiles of the four model drugs following their respective standard dosing regimens (as shown in Table 1). Profiles were simulated in a typical individual (body weight of 70-kg and body surface area of 1.8 m2) using the published population pharmacokinetic parameters in cancer patients (as summarized in Table 1).
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Figure S1 Population mean plasma concentration – time profiles of the four model drugs following their respective standard dosing regimens (as shown in Table 1). Profiles were simulated in a typical individual (body weight of 70-kg and body surface area of 1.8 m2) using the published population pharmacokinetic parameters in cancer patients (as summarized in Table 1).
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose:Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design:A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results:Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions:These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose:Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design:A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results:Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions:These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S2 Drug-specific parameters
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S2 Drug-specific parameters
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S1 System-specific parameters for the 9-CNS PBPK model*
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Supplementary Table S1 System-specific parameters for the 9-CNS PBPK model*
- 27 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5140-5152
Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose: Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design: A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results: Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions: These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- 27 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5140-5152
Focused Ultrasound–Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling
Purpose: Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design: A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results: Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions: These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.
- Open Access
Plasma 4β-Hydroxycholesterol Predicts Ribociclib CYP3A-Mediated Metabolism, but Not Plasma Exposure, in Patients with Primary Brain Cancer
Background/Objectives: This study aimed to evaluate the potential utility of plasma 4β-hydroxycholesterol (4β-OHC) as an endogenous biomarker of hepatic CYP3A activity for predicting ribociclib metabolism and systemic pharmacokinetics in patients with primary brain cancer. Methods: Plasma concentration data for ribociclib and its major metabolite, LEQ803, were obtained from 46 patients receiving oral ribociclib at daily doses of 400, 600, or 900 mg for 5 days. Plasma 4β-OHC concentrations and 4β-OHC/cholesterol ratios were determined by LC–MS/MS at baseline and at 4 and 24 h after ribociclib administration on day 5. A parent–metabolite population pharmacokinetic model was developed to simultaneously characterize ribociclib and LEQ803 disposition and identify clinical covariates influencing their pharmacokinetics. Results: The parent–metabolite model adequately described the multiple-dose plasma concentration–time profiles of ribociclib and LEQ803. On-treatment plasma 4β-OHC concentration was identified as a significant predictor for CYP3A-mediated ribociclib metabolism to LEQ803, accounting for ~36% of interindividual variability in the metabolic clearance. Plasma 4β-OHC showed limited ability to predict total apparent oral clearance or systemic exposure of ribociclib. Conclusions: These findings support the clinical utility of plasma 4β-OHC as an endogenous biomarker of hepatic CYP3A activity for predicting CYP3A-mediated metabolism of substrate drugs such as ribociclib, while highlighting its limitation for predicting total apparent oral clearance of drugs undergoing intestinal first-pass metabolism and elimination through multiple pathways. These results underscore the importance of considering the relative contribution of hepatic CYP3A metabolism to overall drug disposition when evaluating translational utility of endogenous CYP3A biomarkers in clinical pharmacology.
Open AccessPlasma 4β-Hydroxycholesterol Predicts Ribociclib CYP3A-Mediated Metabolism, but Not Plasma Exposure, in Patients with Primary Brain Cancer
Background/Objectives: This study aimed to evaluate the potential utility of plasma 4β-hydroxycholesterol (4β-OHC) as an endogenous biomarker of hepatic CYP3A activity for predicting ribociclib metabolism and systemic pharmacokinetics in patients with primary brain cancer. Methods: Plasma concentration data for ribociclib and its major metabolite, LEQ803, were obtained from 46 patients receiving oral ribociclib at daily doses of 400, 600, or 900 mg for 5 days. Plasma 4β-OHC concentrations and 4β-OHC/cholesterol ratios were determined by LC–MS/MS at baseline and at 4 and 24 h after ribociclib administration on day 5. A parent–metabolite population pharmacokinetic model was developed to simultaneously characterize ribociclib and LEQ803 disposition and identify clinical covariates influencing their pharmacokinetics. Results: The parent–metabolite model adequately described the multiple-dose plasma concentration–time profiles of ribociclib and LEQ803. On-treatment plasma 4β-OHC concentration was identified as a significant predictor for CYP3A-mediated ribociclib metabolism to LEQ803, accounting for ~36% of interindividual variability in the metabolic clearance. Plasma 4β-OHC showed limited ability to predict total apparent oral clearance or systemic exposure of ribociclib. Conclusions: These findings support the clinical utility of plasma 4β-OHC as an endogenous biomarker of hepatic CYP3A activity for predicting CYP3A-mediated metabolism of substrate drugs such as ribociclib, while highlighting its limitation for predicting total apparent oral clearance of drugs undergoing intestinal first-pass metabolism and elimination through multiple pathways. These results underscore the importance of considering the relative contribution of hepatic CYP3A metabolism to overall drug disposition when evaluating translational utility of endogenous CYP3A biomarkers in clinical pharmacology.
- Open Access
- 5 March 2026
- Published by Elsevier in Software Impacts
- Vol. 28
TumorPred: A computational framework implemented via an R/Shiny web application for parameter estimation and sensitivity analysis in compartmental brain modeling
- 5 March 2026
- Published by Elsevier in Software Impacts
- Vol. 28
Open AccessTumorPred: A computational framework implemented via an R/Shiny web application for parameter estimation and sensitivity analysis in compartmental brain modeling
- Open Access
- 16 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 524
Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization
Background: This study aimed to develop a population pharmacokinetic (PK) model that characterized the plasma concentration–time profiles of the total and unbound pamiparib, a PARP inhibitor, in glioblastoma patients and identified patient factors influencing the PK. Methods: The total and unbound pamiparib plasma concentration data were obtained from 41 glioblastoma patients receiving 60 mg of pamiparib twice daily. Nonlinear mixed-effects modeling was performed using Monolix (2024R1) to simultaneously fit the total and unbound drug plasma concentration data. The covariate model was developed by covariate screening using generalized additive modeling followed by stepwise covariate modeling. Model simulations were performed following oral doses of 10–60 mg BID. Results: The total and unbound pamiparib plasma concentration–time profiles were best described by a one-compartment model with first-order absorption and elimination. Creatinine clearance and age were the significant covariates on the apparent volume of distribution (V/F) and apparent clearance (CL/F), respectively, explaining ~22% and ~5% of IIV of V/F and CL/F. Population estimates of the absorption rate constant (Ka), V/F, CL/F, and unbound fraction for the total drug were 1.58 h−1, 44 L, 2.59 L/h, and 0.041. Model simulations suggested that doses as low as 20 mg BID may be adequate for therapeutic effects in a general patient population, assuming that a target engagement ratio (i.e., unbound Css,min/IC50) of 5 or above is sufficient for full target engagement. Conclusions: The total and unbound pamiparib plasma PK are well characterized by a linear one-compartment model, with creatinine clearance as the significant covariate on V/F. Model simulations support further clinical investigation into dose reduction to optimize the benefit-to-risk ratio of pamiparib, particularly in combination therapies.
- 16 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 524
Open AccessPopulation Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization
Background: This study aimed to develop a population pharmacokinetic (PK) model that characterized the plasma concentration–time profiles of the total and unbound pamiparib, a PARP inhibitor, in glioblastoma patients and identified patient factors influencing the PK. Methods: The total and unbound pamiparib plasma concentration data were obtained from 41 glioblastoma patients receiving 60 mg of pamiparib twice daily. Nonlinear mixed-effects modeling was performed using Monolix (2024R1) to simultaneously fit the total and unbound drug plasma concentration data. The covariate model was developed by covariate screening using generalized additive modeling followed by stepwise covariate modeling. Model simulations were performed following oral doses of 10–60 mg BID. Results: The total and unbound pamiparib plasma concentration–time profiles were best described by a one-compartment model with first-order absorption and elimination. Creatinine clearance and age were the significant covariates on the apparent volume of distribution (V/F) and apparent clearance (CL/F), respectively, explaining ~22% and ~5% of IIV of V/F and CL/F. Population estimates of the absorption rate constant (Ka), V/F, CL/F, and unbound fraction for the total drug were 1.58 h−1, 44 L, 2.59 L/h, and 0.041. Model simulations suggested that doses as low as 20 mg BID may be adequate for therapeutic effects in a general patient population, assuming that a target engagement ratio (i.e., unbound Css,min/IC50) of 5 or above is sufficient for full target engagement. Conclusions: The total and unbound pamiparib plasma PK are well characterized by a linear one-compartment model, with creatinine clearance as the significant covariate on V/F. Model simulations support further clinical investigation into dose reduction to optimize the benefit-to-risk ratio of pamiparib, particularly in combination therapies.